DeFI Study: A randomized, double-blind, placebo-controlled, phase III trial of Nirogacestat versus placebo in adult patients with progressing desmoid tumours/aggressive fibromatosis

E7389-G000-213 (BOLD): A phase I/II single-arm study evaluating the safety and efficacy of Eribulin Mesilate in combination with Irinotecan in children with refractory or recurrent solid tumours

E7080-G000-230 (OLIE): A multicenter, open-label, randomized phase II study to compare the efficacy and safety of Lenvatinib in combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in children, adolescents and young adults with relapsed or refractory Osteosarcoma

HGUS EORTC 62113: A randomised double-blind phase II study evaluating the role of maintenance Cabozantinib in high grade undifferentiated uterine sarcoma (HGUS) or response to Doxorubicin +/-Ifosfamide or in metastatic first line treatment

IMRISA phase II study of intensity modulated radiotherapy (IMRT) in primary bone and soft tissue sarcoma

INTRIGUE: A phase III, interventional, randomised, multicentre, open-label study of DCC-2618 vs sunitinib in patients with advanced gastrointestinal stromal tumours after treatment with imatinib

KCP-330-020 (SEAL): A phase II/III multicentre, randomised, double-blind study of Selinexor (KPT - 330) verus placebo in patient with advanced unresectable differentiated liposarcoma

RAPPER: Radiogenomics: Assessment of polymorphisms for predicting the effects of radiotherapy

REDUCE (EORTC 1762): Reduced dose-density of denosumab for maintenance therapy of unresectable giant cell tumour of bone: a multicentre phase II study